

# CITATION REPORT

List of articles citing

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations

DOI: 10.2147/ppa.s105241

Patient Preference and Adherence, 2016, 10, 1205-15.

**Source:** <https://exaly.com/paper-pdf/63044963/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Nitric Oxide Synthase in Male Urological and Andrologic Functions. <b>2017</b> ,		3
3	Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction. <i>Investigative and Clinical Urology</i> , <b>2020</b> , 61, 81-87	1.9	1
2	Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. <i>Sexual Medicine Reviews</i> , <b>2019</b> , 7, 430-441	5.6	13
1	Discontinuation Rates of Tadalafil Alone and in Combination with $\alpha$ -Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-14		0